| |
|
|
|
|
|
 |
| |
|
Æä¸£µòÁ¤100mg [Phenazopyridine HCl]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A16204941]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2007.01.01)(ÇöÀç¾à°¡)
\152 ¿ø/1Á¤(2004.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ °æ¿ìÀÇ ÇϺοä·ÎÁ¡¸· ÀÚ±ØÀ¸·Î ÀÎÇÑ ÅëÁõ, ÀÛ¿°¨, ºÒÄè°¨ÀÇ ÀϽÃÀû ¿ÏÈ
¿ë·Î°¨¿°, »óó, ¼ö¼ú, ³»½Ã°æ, ¼Ò½ÄÀÚ(sounds) ¶Ç´Â Ä«ÅןÀÇ »ðÀÔ½Ã
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:412201ATB ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
¼ºÀÎ : 1ÀÏ 3ȸ, 1ȸ 200¹Ð¸®±×¶÷(1Á¤)À» ½Ä»çÁß ¶Ç´Â ½ÄÈÄ Áï½Ã º¹¿ëÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾àÀÇ ¼ººÐ¿¡ ´ëÇØ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) Æ÷µµ´ç-6-Àλê Å»¼ö¼ÒÈ¿¼Ò °áÇÌÁõ(Clucose-6-phosphate dehydrogenase deficiency) ȯÀÚ
|
| ½ÅÁßÅõ¿© |
1) °£¿° ȯÀÚ
2) ½ÅºÎÀü ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) ¼Òȱâ°è : ¶§¶§·Î ¼ÒȺҷ®, À§°æ·Ã ¶Ç´Â À§Àå¿¡ ÅëÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) Á¤½Å½Å°æ°è : ¶§¶§·Î µÎÅë, ¾îÁö·¯¿ò µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, ÇѸíÀÇ È¯ÀÚ¿¡°Ô¼ ¹«±Õ¼º ¼ö¸·¿°(¹ß¿, Á¤½ÅÈ¥¹Ì)ÀÌ ¹ß»ýÇß´Ù´Â º¸°í°¡ ÀÖ´Ù.
3) °ú¹ÎÁõ : µå¹°°Ô ¹ßÀû µî ¾Ë·¯Áö¼º ÇǺο° µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç¿Í »óÀÇÇÑ´Ù.
4) ¼øÈ¯°è : µå¹°°Ô ¿ëÇ÷¼º ºóÇ÷(È£Èí°ï¶õ, ÇãÅ», ºñÁ¤»óÀûÀÎ ÇǷΰ¨ µîÀÇ Áõ»ó) ¶Ç´Â ¸ÞÆ®Çì¸ð±Û·ÎºóÇ÷Áõ(ÇǺο¡ û»ö ¶Ç´Â ÀÚÁÖ»ö ¾ó·èÀÌ »ý±â°í È£ÈíÀÌ °¡ºüÁö´Â µîÀÇ Áõ»ó)À» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç¿Í »óÀÇÇÑ´Ù. ÀÌ·¯ÇÑ ºÎÀÛ¿ëÀº °ú·®Åõ¿©³ª ½ÅºÎÀü ȯÀÚÀÇ °æ¿ì Àß ÀϾ ¼ö ÀÖÀ¸¸ç, ƯÈ÷ Æ÷µµ´ç-6-Å»¼ö¼ÒÈ¿¼Ò °áÇÌÁõ ȯÀÚÀÇ °æ¿ì ¿ëÇ÷¼º ºóÇ÷ÀÌ Àß ÀϾ ¼ö ÀÖ´Ù.
5) °£ : µå¹°°Ô °£ µ¶¼ºÀ¸·Î ÀÎÇØ ´« ¶Ç´Â ÇǺΰ¡ ³ë¶þ°Ô º¯ÇÒ ¼ö ÀÖÀ¸¸ç ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç¿Í »óÀÇÇÑ´Ù.
6) ½ÅÀå : µå¹°°Ô ½ÅÀå±â´É ÀÌ»óÀ¸·Î Ç÷¾ÐÀÌ »ó½ÂÇÏ°í ¼ûÀÌ °¡»Ú¸ç, ´¢·®ÀÇ ±Þ°ÝÇÑ °¨¼Ò, ¸»´Ü ºÎÁ¾, °¥Áõ, üÁßÁõ°¡ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç¿Í »óÀÇÇÑ´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Phenazopyridine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Phenazopyridine's mechanism of action is not well known, and only basic information on its interaction with the body is available. It is known that the chemical has a direct topical analgesic effect on the mucosa lining of the urinary tract.
|
| Pharmacology |
Phenazopyridine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Phenazopyridine is a local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.
|
| Half-life |
Phenazopyridine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Phenazopyridine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
Phenazopyridine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´ë»ç : °£ ¹× ±âŸ Á¶Á÷¿¡¼ ´ë»çµÊ
- ¼Ò½Ç : ¼Òº¯(ÁÖ ÀÛ¿ëºÎÀ§). ¹Ìº¯Èü·Î¼ ½Å¼ÓÇÏ°Ô ½Å¹è¼³µÊ (65%)
|
| Biotransformation |
Phenazopyridine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Likely hepatic but also in other tissues. One of the metabolites is acetaminophen.
|
| Toxicity |
Phenazopyridine¿¡ ´ëÇÑ Toxicity Á¤º¸ Methemoglobinemia generally follows a massive, acute overdose.
|
| Drug Interactions |
Phenazopyridine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Description |
Phenazopyridine¿¡ ´ëÇÑ Description Á¤º¸ A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. [PubChem]
|
| Dosage Form |
Phenazopyridine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Tablet OralTablet Oral
|
| Drug Category |
Phenazopyridine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anesthetics, Local
|
| Smiles String Canonical |
Phenazopyridine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC1=NC(N)=C(C=C1)N=NC1=CC=CC=C1
|
| Smiles String Isomeric |
Phenazopyridine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
|
| InChI Identifier |
Phenazopyridine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C11H11N5/c12-10-7-6-9(11(13)14-10)16-15-8-4-2-1-3-5-8/h1-7H,(H4,12,13,14)/b16-15+/f/h12-13H2
|
| Chemical IUPAC Name |
Phenazopyridine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 3-phenyldiazenylpyridine-2,6-diamine
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-10-25
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|